Syndax Presents Positive Revuforj® (Revumenib) Data In Acute Leukemias From Multiple Trials, Including The SAVE Combination And AUGMENT-101 Trials, At 66Th ASH Annual Meeting
Syndax Presents Positive Revuforj® (Revumenib) Data In Acute Leukemias From Multiple Trials, Including The SAVE Combination And AUGMENT-101 Trials, At 66Th ASH Annual Meeting . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 – 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108967438/Syndax-Presents-Positive-Revuforj-Revumenib-Data-In-Acute-Leukemias-From-Multiple-Trials-Including-The-SAVE-Combination-And-AUGMENT-101-Trials-At-66Th-ASH-Annual-Meeting
2024-12-07
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 – 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML ...
Syndax Presents Positive Revuforj® (Revumenib) Data In Acute Leukemias From Multiple Trials, Including The SAVE Combination And AUGMENT-101 Trials, At 66Th ASH Annual Meeting